Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States

CONCLUSION: These real-world outcomes are consistent with ALCANZA results, demonstrating favorable outcomes with BV vs. OST in patients with CTCL previously treated with ≥1 systemic therapy.PMID:37919137 | DOI:10.1016/j.clml.2023.10.001

Source: Clinical Lymphoma and Myeloma - November 2, 2023 Category: Cancer & Oncology Authors: Stefan K Barta Nicholas Liu Maral DerSarkissian Rose Chang Mingchen Ye Mei Sheng Duh Andy Surinach Michelle Fanale Kristina S Yu Source Type: research